07:00 Wed 20 Mar 2019
Physiomics PLC - Conference Attendance and Presentation
20th
("
Conference attendance and presentation
In addition, the Company will be presenting two original posters in the session "PO.BSB02.01 - Convergence Science for Therapeutics and Precision Medicine"-Section 30, scheduled 31st
· A precision dosing application for prostate cancer chemotherapy (Abstract #677)
This is our first tool based on AI (machine learning) technologies. Currently dosing of docetaxel in prostate cancer is based on population averages, leading to effective under or over dosing in a significant number of patients. Our tool could, if approved, provide information that could assist clinicians in adapting chemotherapy dosing for individual patients. This offers the possibility of enhancing both the safety and efficacy of an existing standard of care without the costs typically associated with a new pharmaceutical product.
· Predicting the effect of radiotherapy on tumour growth inhibition and time to progression in head and neck cancer (Abstract #680)
Over recent years, driven by a number of actual client projects, we have extended our Virtual Tumour™ technology from a tool primarily used to predict preclinical tumour growth inhibition into one that can also help clients understand the likely response to their drug(s) in the clinic. The most recent evolution of Virtual Tumour™ has been to enhance its ability to model the longer-term re-growth of clinical tumours which can exhibit widely varying times to re-growth/ progression following irradiation. As time to progression is the strongest predictor of survival, we believe that this enhanced capability increases the value of our predictions to our clients.
According to AACR, it is the oldest and largest scientific organisation in the world focused on every aspect of high-quality, innovative cancer research. Its annual conference is attended by representatives from public and private sector organisations from the very small to the largest global players, with over 22,000 participants attending in 2018.
More information about the conference may be found at:
https://www.aacr.org/MEETINGS/PAGES/MEETINGDETAIL.ASPX?EVENTITEMID=174
Enquiries:
Dr Jim Millen, CEO
+44 (0)1865 784 980
Katy Mitchell
James Sinclair-Ford
+44 (0) 161 832 2174
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
About Physiomics
Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.
Physiomics senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE